Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals and immunocompromised patients in the course of an anti-SARS-CoV-2 BNT162b2 mRNA prospective, open-label clinical vaccine trial. See trial registration description in notes. Results revealed preserved NK cell numbers, frequencies, subsets, phenotypes, and function as assessed through consecutive peripheral blood samplings at 0, 10, 21, and 35 days following vaccination. A positive correlation was observed between the frequency of NKG2C + NK cells at baseline (Day 0) and anti-SARS-CoV-2 Ab titers following BNT162b2 mRNA vaccination at Day 35. The present results provide basic insights in regards to NK cells in the context of mRNA vaccination, and have relevance for future mRNA-based vaccinations against COVID-19, other viral infections, and cancer. Trial registration : The current study is based on clinical material from the COVAXID open-label, non-randomized prospective clinical trial registered at EudraCT and clinicaltrials.gov (no. 2021–000175-37). Description: https://clinicaltrials.gov/ct2/show/NCT04780659?term=2021-000175-37&draw=2&rank=1 . Supplementary Information The online version contains supplementary material available at 10.1186/s10020-022-00443-2.
【저자키워드】 COVID-19, SARS-CoV-2, clinical trial, Innate immunity, mRNA vaccine, NK cells, anti-SARS-CoV-2 antibodies, BNT162b2 mRNA vaccine, NKG2C, 【초록키워드】 mRNA vaccination, immune response, vaccination, Open-label, Cancer, NK cell, Immunocompromised patients, NK cells, anti-SARS-CoV-2, viral infections, Immunocompromised patient, Peripheral blood, BNT162b2, mRNA, immune responses, Immunocompromised, immune cells, Innate immune cells, BNT162b2 mRNA vaccination, BNT162b2 mRNA, Frequency, adaptive immune responses, Prospective clinical trial, Phenotypes, Trial registration, supplementary material, frequencies, healthy individuals, positive correlation, Registered, EudraCT, description, vaccine trial, Effect, clinical material, Course, Result, Day, characterized, non-randomized, in healthy individual, baseline, mRNA-based, preserved, 【제목키워드】 Vaccine, NK cell, outcome, anti-SARS-CoV-2, healthy, immunocompromised individual,